ArticleJournal of cachexia, sarcopenia and muscle2024
Metabolic syndrome and cardiovascular disease in cancer survivors.
Article in Journal of cachexia, sarcopenia and muscle, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of combined lifestyle intervention on cardiometabolic risk in cancer survivors: A systematic review and meta-analysis of randomized controlled trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Persistent Cardiovascular Burden and Independent Association Among Cancer Survivors in the United States, 2016 to 2024.Journal of the American Heart Association · 2026Article
- Exploring Long-Term Exercise and Fitness Maintenance Using Group Versus Individual Training in a Diverse Group of Breast Cancer Survivors.Healthcare (Basel, Switzerland) · 2026Article
- Association of metabolic markers, inflammatory biomarkers, and sedentary time with comorbidities among cancer patients: Results from NHANES 2021-2023.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Metabolic Syndrome Is Associated with Increased Plasma Fibroblast Growth Factor 21 (FGF21) in Postmenopausal Breast Cancer Survivors: Implications for Therapy and Diagnosis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Multidimensional nomogram for prediction of cardiovascular disease risk in cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Association of the C-reactive protein-triglyceride-glucose index with the risk of incident cardiovascular disease in rectal cancer survivors.Frontiers in cardiovascular medicine · 2026Article
- Association between metabolic syndrome and mortality among breast cancer survivors: a prospective cohort study.Frontiers in endocrinology · 2026Article
- Associations of Changes in Metabolic Syndrome Status and Risk Factor Count With Incident Cardiovascular Events Among Cancer Survivors.Journal of lipid and atherosclerosis · 2026Article
- Metabolic syndrome and related factors in early-old and late-old cancer survivors.Physical activity and nutrition · 2025Article
- Self-reported weight change and diet quality in relation to metabolic syndrome among Korean cancer survivors: a cross-sectional study using the Korea National Health and Nutrition Examination Survey 2019-2021.Korean journal of community nutrition · 2025Article
- Interaction effects between serum 25(OH)D and CRP status on cancer related mortality in adult cancer survivors.Scientific reports · 2025Article
- In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and Therapy.Cancers · 2025Review
- Cardiovascular diseases in patients with cancer: A comprehensive review of epidemiological trends, cardiac complications, and prognostic implications.Chinese medical journal · 2025Review
- Unraveling the anti-inflammatory effects of Mediterranean diet in patients with cancer remission.Frontiers in immunology · 2025Article
- Association Between Metabolic Syndrome and Incident Cervical Cancer: A Retrospective Cohort Study.Journal of obesity · 2025Article
- Global Research Trends and Hotspots in the Role of Cholesterol in Colorectal Cancer: A Bibliometric Analysis.Human mutation · 2025Article
- Metabolic syndrome and cardiovascular disease in cancer survivors.Journal of cachexia, sarcopenia and muscle · 2024Article
- Additive impact of metabolic syndrome and sarcopenia on all-cause and cause-specific mortality: an analysis of NHANES.Frontiers in endocrinology · 2024Article
- Mechanisms of inflammatory microenvironment formation in cardiometabolic diseases: molecular and cellular perspectives.Frontiers in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe risk of subsequent cardiovascular disease (CVD) is high in cancer survivors. Although metabolic syndrome is an established risk factor for CVD, its association with cancer survivors has not yet been established. This study aimed to clarify whether metabolic syndrome is associated with subsequent CVD risk in patients with cancer using a nationwide epidemiological dataset.
methodsWe retrospectively analysed 53 510 patients with a history of breast, colorectal, or stomach cancer, which is reportedly a major site for developing cancer in Japan. Study participants were categorized into two groups based on the presence of metabolic syndrome, defined using the Japanese criteria (high waist circumference and ≥2 metabolic parameters including elevated blood pressure, elevated triglycerides, reduced high-density lipoprotein cholesterol, or elevated fasting plasma glucose). The clinical outcomes were collected between 2005 and 2021. The primary endpoint was defined as the composite CVD outcome, including myocardial infarction, angina pectoris, stroke, and heart failure.
resultsThe median patient age was 54 years, and 37.5% of the patients were men. Metabolic syndrome was observed in 5558 (10.4%) patients. Over a mean follow-up period of 973 ± 791 days, 3085 composite CVD outcomes were recorded. Multivariable Cox regression analyses showed that metabolic syndrome was associated with a greater risk of developing CVD events (HR = 1.29, 95% CI = 1.15-1.45). Metabolic syndrome was also associated with an increased risk of CVD in patients with a follow-up period ≥1 year (HR = 1.33, 95% CI = 1.15-1.53). This relationship was also observed when metabolic syndrome was defined according to the International Diabetes Federation criteria (HR = 1.34, 95% CI = 1.21-1.49) and the National Cholesterol Education Program Adult Treatment Panel III criteria (HR = 1.32, 95% CI = 1.19-1.46). Subgroup analyses showed that the relationship between metabolic syndrome and incident CVD was more pronounced in the non-obese participants than in the obese participants.
conclusionsMetabolic syndrome is associated with a greater risk of developing CVD, even among cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.